IRADIMED CORPORATION (IRMD) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
74/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseIRMD / S&P -0.50% / 15.20% |
LoseIRMD / S&P 11.21% / 15.00% |
LoseIRMD / S&P 10.49% / 50.40% |
| 2026-Q12/3 |
WinIRMD / S&P -0.86% / -4.33% |
WinIRMD / S&P 14.81% / 11.30% |
LoseIRMD / S&P 18.06% / 27.70% |
| 2025-Q43/3 |
WinIRMD / S&P 37.69% / 2.65% |
WinIRMD / S&P 14.43% / 9.00% |
WinIRMD / S&P 16.67% / 13.40% |
| 2025-Q32/3 |
WinIRMD / S&P 19.30% / 8.12% |
WinIRMD / S&P 12.91% / 4.61% |
LoseIRMD / S&P 13.01% / 13.45% |
| 2025-Q23/3 |
WinIRMD / S&P 14.29% / 10.94% |
WinIRMD / S&P 11.73% / 4.83% |
WinIRMD / S&P 10.96% / 10.63% |
| 2025-Q11/3 |
LoseIRMD / S&P -4.29% / -4.27% |
WinIRMD / S&P 11.04% / 4.98% |
LoseIRMD / S&P 9.93% / 10.57% |
| 2024-Q43/3 |
WinIRMD / S&P 9.67% / 2.41% |
WinIRMD / S&P 11.71% / 5.25% |
WinIRMD / S&P 10.29% / 6.15% |
| 2024-Q33/3 |
WinIRMD / S&P 14.84% / 5.89% |
WinIRMD / S&P 13.23% / 5.89% |
WinIRMD / S&P 12.31% / 6.11% |
| 2024-Q22/3 |
LoseIRMD / S&P 0.24% / 4.28% |
WinIRMD / S&P 16.05% / 5.38% |
WinIRMD / S&P 24.79% / 5.12% |
| 2024-Q12/3 |
LoseIRMD / S&P -7.33% / 10.56% |
WinIRMD / S&P 19.87% / 5.71% |
WinIRMD / S&P 28.18% / 5.59% |
| 2023-Q42/3 |
LoseIRMD / S&P 8.49% / 11.69% |
WinIRMD / S&P 23.00% / 6.81% |
WinIRMD / S&P 32.04% / 7.78% |
| 2023-Q32/3 |
LoseIRMD / S&P -7.06% / -3.27% |
WinIRMD / S&P 25.17% / 7.52% |
WinIRMD / S&P 25.00% / -5.03% |
| 2023-Q23/3 |
WinIRMD / S&P 21.32% / 8.74% |
WinIRMD / S&P 25.23% / 9.50% |
WinIRMD / S&P 20.62% / -8.57% |
| 2023-Q13/3 |
WinIRMD / S&P 43.36% / 7.50% |
WinIRMD / S&P 25.76% / 10.77% |
WinIRMD / S&P 32.53% / -15.69% |
| 2022-Q42/3 |
LoseIRMD / S&P -5.89% / 7.56% |
WinIRMD / S&P 27.48% / 11.88% |
WinIRMD / S&P 39.19% / -17.99% |
| 2022-Q32/3 |
LoseIRMD / S&P -11.43% / -4.88% |
WinIRMD / S&P 30.72% / 13.47% |
WinIRMD / S&P 116.67% / -1.41% |
| 2022-Q22/3 |
LoseIRMD / S&P -24.31% / -16.10% |
WinIRMD / S&P 35.52% / 13.71% |
WinIRMD / S&P 162.16% / 11.04% |
| 2022-Q13/3 |
WinIRMD / S&P -0.98% / -4.60% |
WinIRMD / S&P 39.17% / 15.97% |
WinIRMD / S&P 937.50% / 42.23% |
| 2021-Q43/3 |
WinIRMD / S&P 37.57% / 11.03% |
WinIRMD / S&P 31.83% / 15.00% |
WinIRMD / S&P 572.73% / 96.40% |
| 2021-Q32/3 |
WinIRMD / S&P 14.21% / 0.58% |
WinIRMD / S&P 12.99% / 10.77% |
LoseIRMD / S&P 50.00% / 69.42% |
| 2021-Q21/3 |
WinIRMD / S&P 14.12% / 8.55% |
LoseIRMD / S&P -2.88% / 6.58% |
LoseIRMD / S&P -13.95% / 51.81% |
| 2021-Q11/3 |
WinIRMD / S&P 13.03% / 6.17% |
LoseIRMD / S&P -16.75% / -1.06% |
LoseIRMD / S&P -89.61% / 7.39% |
| 2020-Q40/3 |
LoseIRMD / S&P 6.64% / 12.15% |
LoseIRMD / S&P -17.65% / -3.72% |
LoseIRMD / S&P -85.90% / -33.42% |
| 2020-Q30/3 |
LoseIRMD / S&P -7.88% / 8.93% |
LoseIRMD / S&P -5.29% / -2.04% |
LoseIRMD / S&P -51.52% / -27.10% |
| 2020-Q21/3 |
LoseIRMD / S&P 8.71% / 20.54% |
WinIRMD / S&P 8.06% / -0.46% |
LoseIRMD / S&P -34.85% / -27.11% |
| 2020-Q13/3 |
WinIRMD / S&P -8.68% / -19.60% |
WinIRMD / S&P 22.00% / 3.47% |
WinIRMD / S&P 28.33% / -14.75% |
| 2019-Q43/3 |
WinIRMD / S&P 11.23% / 9.07% |
WinIRMD / S&P 26.54% / 5.36% |
WinIRMD / S&P 50.00% / 2.99% |
| 2019-Q33/3 |
WinIRMD / S&P 2.79% / 1.70% |
WinIRMD / S&P 24.86% / 5.02% |
WinIRMD / S&P 69.23% / 0.21% |
| 2019-Q22/3 |
LoseIRMD / S&P -27.20% / 4.30% |
WinIRMD / S&P 25.07% / 6.64% |
WinIRMD / S&P 214.29% / 8.65% |
| 2019-Q13/3 |
WinIRMD / S&P 14.84% / 13.65% |
WinIRMD / S&P 26.94% / 8.12% |
WinIRMD / S&P 361.54% / 14.29% |
| 2018-Q42/3 |
LoseIRMD / S&P -34.16% / -13.52% |
WinIRMD / S&P 31.88% / 9.05% |
WinIRMD / S&P 1200.00% / 18.23% |
| 2018-Q33/3 |
WinIRMD / S&P 79.04% / 7.71% |
WinIRMD / S&P 28.78% / 10.21% |
WinIRMD / S&P 200.00% / 19.06% |
| 2018-Q22/3 |
WinIRMD / S&P 44.10% / 3.43% |
WinIRMD / S&P 10.39% / 9.03% |
LoseIRMD / S&P -12.50% / 14.46% |
| 2018-Q10/3 |
LoseIRMD / S&P -4.95% / -0.76% |
LoseIRMD / S&P -12.78% / 7.68% |
LoseIRMD / S&P -67.50% / 12.46% |
| 2017-Q41/3 |
WinIRMD / S&P 57.81% / 6.64% |
LoseIRMD / S&P -28.97% / 7.03% |
LoseIRMD / S&P -93.44% / 13.82% |
| 2017-Q31/3 |
WinIRMD / S&P 11.63% / 4.48% |
LoseIRMD / S&P -36.65% / 5.68% |
LoseIRMD / S&P -81.16% / 17.57% |
| 2017-Q20/3 |
LoseIRMD / S&P -3.37% / 3.09% |
LoseIRMD / S&P -32.03% / 4.83% |
LoseIRMD / S&P -66.20% / 17.74% |
| 2017-Q10/3 |
LoseIRMD / S&P -19.82% / 6.07% |
LoseIRMD / S&P -14.51% / 3.67% |
LoseIRMD / S&P -40.30% / 13.32% |
| 2016-Q41/3 |
LoseIRMD / S&P -34.67% / 3.82% |
WinIRMD / S&P 2.86% / 2.09% |
LoseIRMD / S&P 1.67% / 7.05% |
| 2016-Q32/3 |
LoseIRMD / S&P -21.92% / 3.85% |
WinIRMD / S&P 33.84% / 0.20% |
WinIRMD / S&P 56.82% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IRMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 21.76% | 20.78% |
| Annualized return | 21.76% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IRMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 166.33% | 83.14% |
| Annualized return | 21.64% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | IRMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 444.00% | 319.30% |
| Annualized return | 18.46% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |